Insider buying last 90 days
No open-market insider purchases were filed for EXEL in the last 90 days.
From Form 4 filings, dated to when each was filed.
Nov 13 close
Exelixis moved higher this week on third-quarter results showing revenue and GAAP net income rising year-over-year, driven by the cabozantinib franchise, with full-year 2026 revenue guidance maintained even as the company lowered its effective tax-rate range. The stock also touched an all-time high of $73.49, and continued coverage has highlighted progress on zanzalintinib alongside Exelixis' international revenue exposure.
The shares closed at $71.74, up 3.1% on the day, sitting above both the 50-day average of $61.27 and the 200-day average of $51.70, with the 50-day above the 200-day. The GekkoIndex reads 44.9, placing EXEL in the Distribution zone. Despite the recent strength, price remains 24.7% below the Gekko Fair Value of $95.25.
The next earnings date falls on 9 February 2027, 91 days out and beyond a typical 20-trading-day holding window, with the prior report on 5 August 2026 showing an EPS beat of $0.82 versus $0.75 estimated, though the shares reacted -6.8% afterward. No insider, Congress or unusual options activity appears in the respective 90-day and 30-day windows, and one trailblazer holder is noted. Seasonally, the next 20 trading days have averaged -0.2% over 5 years, rising in 4 of them, which is worth noting alongside the current Distribution reading.
Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.
Exelixis scores 3 supportive, 2 mixed and 0 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive2 mixed0 headwinds
Above 50 and 200-day
Close $69.00 is above the 50-day ($62.29) and 200-day ($52.24) averages, and the 50-day is above the 200-day.
See the chart53.2, Neutral
Reading 53.2 is in the Neutral zone.
See the GekkoIndex25.6% below
Price is 25.6% below Gekko Fair Value (more than 5% below).
See fair valueNo data
No insider, Congress or unusual options activity in the window.
See smart moneyReports in 86 days
Next report Feb 9, 2027, 86 days away — outside a typical 20-trading-day hold.
See earnings0.0% on average
From this point in the calendar, the next 20 trading days averaged 0% over 5 years, rising in 1 of them.
See seasonalityA description of current data, not a recommendation. How this page works
Exelixis closed at $69.00 on Nov 13, 2026, +58.3% over the past year, inside a 52-week range of $39.71 to $73.69.
Use the left and right arrow keys to read daily values.
Put EXEL on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Exelixis works in cancer treatment, developing and selling drugs aimed at fighting the disease within the United States. It markets CABOMETYX for advanced kidney cancer patients who have already had anti-angiogenic therapy, and COMETRIQ for a form of metastatic thyroid cancer; both draw on the same underlying compound, cabozantinib, which blocks several kinases tied to tumor growth. The company also sells COTELLIC, used alongside other treatments for advanced melanoma, and MINNEBRO, a blood pressure medication cleared for use in Japan. Beyond these approved products, Exelixis is advancing several experimental compounds targeting solid tumors and blood cancers through its research pipeline.
The company relies heavily on collaboration, holding research and licensing agreements with a range of pharmaceutical and biotech partners that support both its marketed drugs and its pipeline candidates. These partnerships span companies involved in drug discovery, antibody technology, and manufacturing, reflecting a business model built around shared development efforts rather than working in isolation.
Exelixis traces its origins to 1994, when it was founded under the name Exelixis Pharmaceuticals, Inc., before adopting its current name in February 2000. The company is headquartered in Alameda, California, and its shares are listed on the NASDAQ under the ticker EXEL.
Exelixis’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 53.2, in the Neutral zone, up 6.5 points over five sessions.
Up 6.5 points over five sessions.
Reading for Nov 13, 2026
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 22 | +0.3% | +5.9% | ||
| Accumulation | 147 | +2.0% | +5.4% | ||
| Neutral (current zone) | 482 | +0.6% | +3.3% | ||
| Distribution | 49 | +1.2% | +1.0% | ||
| Selling | 2 | Too few readings yet | |||
Average EXEL share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
Exelixis trades 25.6% below Gekko Fair Value of $92.75, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Exelixis shares are worth, recalculated every trading day.
$92.75
Gekko Fair Value, Nov 14, 2026
25.6% Undervalued
At the end of Aug 2026 the price was 2.1% above the estimate.
No open-market insider purchases were filed for Exelixis, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
No open-market insider purchases were filed for EXEL in the last 90 days.
From Form 4 filings, dated to when each was filed.
No trades in EXEL were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Exelixis has been buying back its own shares.
From company filings.
1of the funds Gekko tracks holds EXEL.
Exelixis reports on Feb 9, 2027, after the close (86 days away), and beat the EPS estimate in 8 of its last 8 reports.
Feb 9, 2027
Expected after the close, 86 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 5, 2026 | $0.82 est $0.75 | $628.7M est $636.4M | −6.8% |
| May 5, 2026 | $0.87 est $0.77 | $610.8M est $607.5M | +10.3% |
| Feb 10, 2026 | $0.94 est $0.77 | $598.7M est $596.5M | −2.3% |
| Nov 4, 2025 | $0.78 est $0.69 | $597.8M est $590.2M | +6.1% |
| Jul 28, 2025 | $0.75 est $0.65 | $568.3M est $594.9M | −19.0% |
| May 13, 2025 | $0.62 est $0.37 | $555.4M est $499.6M | +20.7% |
| Feb 11, 2025 | $0.55 est $0.49 | $566.8M est $563.2M | −2.1% |
| Oct 29, 2024 | $0.40 est $0.35 | $539.5M est $556.6M | +13.8% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for Exelixis is $61.57, −10.8% from the last close, from 13 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 13 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Nov 13 | Morgan Stanley | $57 | −17.4% |
| Nov 9 | RBC Capital | $58 | −15.9% |
| Nov 5 | Leerink Partners | $58 | −15.9% |
| Nov 2 | H.C. Wainwright | $78 | +13.0% |
| Oct 30 | Barclays | $54 | −21.7% |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Over the next 20 trading days from Nov 14, Exelixis averaged 0.0% across the last 5 years, rising in 1 of them.
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −0.8% | 2 of 5 |
| Next 10 trading days | −0.6% | 2 of 5 |
| Next 15 trading days | −0.4% | 3 of 5 |
| Next 20 trading days | 0.0% | 1 of 5 |
| Next 30 trading days | +2.4% | 3 of 5 |
For scale, EXEL’s typical 20-trading-day move in either direction is about 6.1%.
Exelixis’s market cap is $17.34B, with a P/E ratio of 20.9 and revenue of $2.50B over the last twelve months.
Coverage of Exelixis this week reads positive: 3 positive, 2 neutral and 1 negative headlines.
Exelixis’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LLYEli Lilly | Neutral | 24.0% above |
| JNJJohnson & Johnson | Neutral | 4.4% above |
| ABBVAbbVie | Neutral | 23.7% above |
| MRKMerck | Neutral | 8.2% below |
| AZNAstraZeneca | Neutral | 34.6% below |
| PFEPfizer | Accumulation | 8.9% below |
A peer links to its own page where one exists.
Exelixis’s market cap is $17.34B at the Nov 13, 2026 close of $69.00, with 244.0M shares outstanding. The shares trade on a P/E ratio of 20.9.
The consensus analyst 12-month price target for Exelixis is $61.57, −10.8% from the last close. Of the 13 firms that rated the stock in the last 90 days, 4 rate it a buy, 8 a hold and 1 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate Exelixis is undervalued: the Nov 13, 2026 close of $69.00 is 25.6% below Gekko Fair Value of $92.75. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
Exelixis is expected to report on Feb 9, 2027, after the market closes (86 days away). Analysts expect earnings of $0.96 per share on revenue of $658.4M. Exelixis beat the earnings estimate in 8 of its last 8 reports, moving 10.1% on average across the report.
Exelixis’s 52-week high is $73.69 and its 52-week low is $39.71; it closed at $69.00 on Nov 13, 2026, +58.3% over the past year.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (trend, fair value and earnings risk), 2 as mixed (gekkoindex and seasonality). The checklist is a description of current data, not a recommendation.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,475 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.